335 related articles for article (PubMed ID: 33203424)
1. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
[TBL] [Abstract][Full Text] [Related]
2. Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
Sanagawa A; Hotta Y; Kondo M; Nishikawa R; Tohkin M; Kimura K
Anticancer Drugs; 2020 Feb; 31(2):183-189. PubMed ID: 31789626
[TBL] [Abstract][Full Text] [Related]
3. Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment.
Wang L; Jian Y; Yang G; Gao W; Wu Y; Zuo L
Clin J Oncol Nurs; 2015 Feb; 19(1):E4-7. PubMed ID: 25689664
[TBL] [Abstract][Full Text] [Related]
4. Acute kidney injury in bortezomib-treated patients with multiple myeloma.
Song SM; Jeon J; Jang HR; Kim K; Huh W; Kim YG; Lee JE
Nephrol Dial Transplant; 2023 Aug; 38(9):2077-2085. PubMed ID: 36662030
[TBL] [Abstract][Full Text] [Related]
5. High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
Oiwa K; Morita M; Kishi S; Okura M; Tasaki T; Matsuda Y; Tai K; Hosono N; Ueda T; Yamauchi T
Anticancer Res; 2016 Dec; 36(12):6655-6662. PubMed ID: 27919998
[TBL] [Abstract][Full Text] [Related]
6. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
Terpos E; Politou M; Rahemtulla A
J Cancer Res Clin Oncol; 2004 Oct; 130(10):623-5. PubMed ID: 15449188
[TBL] [Abstract][Full Text] [Related]
7. Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
Suzuki K; Terui Y; Nishimura N; Ueda K; Mishima Y; Sakajiri S; Yokoyama M; Aiba K; Hatake K
Jpn J Clin Oncol; 2014 May; 44(5):435-41. PubMed ID: 24664944
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Sezer O; Vesole DH; Singhal S; Richardson P; Stadtmauer E; Jakob C; Boral AL; Esseltine DL; Mehta J
Clin Lymphoma Myeloma; 2006 Nov; 7(3):233-5. PubMed ID: 17229340
[TBL] [Abstract][Full Text] [Related]
9. Tumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.
Chang H; Lee SY; Tang TC
Chang Gung Med J; 2011; 34(6 Suppl):70-5. PubMed ID: 22490464
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib-associated tumor lysis syndrome.
Shely RN; Ratliff PD
Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
[TBL] [Abstract][Full Text] [Related]
11. Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report.
Jin F; Yang M; Chen Y; Jiang L; Liu L
Medicine (Baltimore); 2020 Nov; 99(45):e22632. PubMed ID: 33157919
[TBL] [Abstract][Full Text] [Related]
12. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
Jaskiewicz AD; Herrington JD; Wong L
Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases.
Terzi Demirsoy E; Birtas Atesoglu E; Eren N; Gedük A; Mehtap O; Tarkun P; Hacıhanefioğlu A
Tumori; 2019 Dec; 105(6):NP24-NP27. PubMed ID: 30580656
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
15. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.
Montesinos P; Lorenzo I; Martín G; Sanz J; Pérez-Sirvent ML; Martínez D; Ortí G; Algarra L; Martínez J; Moscardó F; de la Rubia J; Jarque I; Sanz G; Sanz MA
Haematologica; 2008 Jan; 93(1):67-74. PubMed ID: 18166787
[TBL] [Abstract][Full Text] [Related]
16. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
[TBL] [Abstract][Full Text] [Related]
17. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]